Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus afternoon versus evening tamoxifen administration pharmacokinetics study
NL-OMON28836Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tamoxifen in breast cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: Difference in tamoxifen pharmacokinetics by dosing time. Planned start Jul 2012; status: not yet recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON28836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28836.